Chronic spontaneous urticaria (CSU) and mast cell activation syndrome (MCAS) represent significant clinical challenges, particularly when patients fail to respond to conventional therapies. Chronic spontaneous urticaria is a mast cell-driven disease that affects approximately 1% of the population, with second-generation non-sedating H1-antihistamines considered first-line treatment; however, a substantial proportion of patients remain refractory and require alternative therapeutic approaches, including anti-IgE antibodies or other agents that inhibit mast cell activation and degranulation. [1]
In recent years, glucagon-like peptide-1 receptor agonists (GLP-1RAs)—originally developed and extensively used for type 2 diabetes and obesity management—have emerged as potential therapeutic agents for inflammatory and autoimmune disorders, including dermatological conditions. This article synthesizes the emerging evidence for using GLP-1 receptor agonists, particularly semaglutide and tirzepatide, in mast cell-driven diseases, exploring the mechanistic basis, clinical case evidence, and future research directions for this novel therapeutic application.Pathophysiology, Treatments, and Emerging Research
-
Ketotifen 1mg (Zaditen) tabletsPrice range: £29.99 through £199.99 -
Ketotifen 1mg capsulesPrice range: £35.99 through £199.99
The Epidemiology and Burden of Antihistamine-Resistant Urticaria
Urticaria and angioedema represent common yet often challenging dermatological conditions affecting quality of life and mental health. Chronic spontaneous urticaria is characterised by recurrent wheals and/or angioedema persisting for more than 6 weeks, representing a substantial clinical challenge. Although international guidelines endorse second-generation H1-antihistamines as first-line therapy, up to 50% of patients remain refractory even at quadruple doses, significantly compromising quality of life and mental well-being. [2]
This high rate of treatment resistance has prompted research into alternative mechanisms and novel therapeutic targets. Chronic spontaneous urticaria patients sometimes do not respond to second-generation antihistamine, and 10–50% patients do not even respond to four-fold the usual dose of nonsedating H1 antihistamine, which further leads to repeated courses of oral corticosteroids to abate the symptoms. [3] The limited efficacy and potential adverse effects associated with escalating antihistamine doses have driven the development of immunomodulatory and biologic therapies.
Current Standard-of-Care Treatments for Antihistamine-Resistant CSU
For patients who fail to respond to conventional H1-antihistamine monotherapy, several second- and third-line therapeutic options have emerged. Omalizumab, an immunoglobulin G humanised monoclonal anti-immunoglobulin E antibody that prevents binding of immunoglobulin E to the high-affinity immunoglobulin E receptor, has shown safety and efficacy in patients with intractable CSU. In well-controlled clinical trials in patients with refractory CSU who received add-on therapy with subcutaneous omalizumab (300 mg every 4 weeks for 12 or 24 weeks), the rates of complete response were significantly higher in the omalizumab group (relative risk, 4.55; P<0.0001). [4]
Omalizumab has established itself as an effective option, though not all patients achieve adequate control. Among antihistamine-resistant chronic spontaneous urticaria patients treated with omalizumab, 65% achieved symptom cessation following a single omalizumab dose, while 21% responded between second and third doses. A subset (7.4%) necessitated increased dosing frequency for symptom control. Additionally, 6.2% showed persistent symptoms despite increased dosing frequency, exhibiting distinctive biomarker profiles indicative of an autoimmune endotype. [5] These treatment response patterns underscore the heterogeneity of CSU pathophysiology and the need for additional therapeutic options.
Beyond omalizumab, dupilumab was recently demonstrated to be effective in patients with antihistamine-resistant CSU, with one case report describing a patient with chronic spontaneous urticaria who did not tolerate or benefit from omalizumab, but showed complete response to dupilumab. [6] This diversity of emerging biologics reflects ongoing efforts to identify and target distinct immunological endotypes within the CSU population.
Mechanistic Foundation: GLP-1 Signaling and Immune Regulation
To understand the potential therapeutic application of GLP-1RAs in mast cell disorders, it is essential to examine the biological basis of GLP-1 signaling in immune modulation. Glucagon-like peptide-1 is a 30-amino acid hormone secreted by L cells in the distal ileum, colon, and pancreatic ? cells, which participates in blood sugar regulation by promoting insulin release, reducing glucagon levels, delaying gastric emptying, increasing satiety, and reducing appetite. GLP-1 specifically binds to the glucagon-like peptide-1 receptor (GLP-1R) in the body, directly stimulating the secretion of insulin by pancreatic beta-cells, promoting proliferation and differentiation, and inhibiting cell apoptosis, thereby exerting a glycaemic lowering effect. Recent studies found that GLP-1 is able to modulate innate immune response in a number of inflammatory diseases. [7]
Recent experimental and clinical evidence has revealed a broader array of immunomodulatory effects of GLP-1 signaling beyond glucose homeostasis. Incretin mimetics, including GLP-1 and GIP receptor agonists, have recently emerged as groundbreaking therapies for obesity and type 2 diabetes. Data mined from the Human Protein Atlas demonstrated expression of receptors for GLP-1 (GLP-1R) and GIP (GIPR) on normal T-cells and NK cells. Further querying showed widespread expression of these receptors across B-cell acute lymphoblastic leukaemia and pancreatic cancer cell lines. [8] These findings indicate that GLP-1 receptor expression extends to multiple immune cell types, providing a plausible mechanism for systemic immunomodulation.
At the cellular level, flow cytometry on human PBMCs from donors across a spectrum of age, ethnicity, and BMI demonstrated modest expression of GLP-1R on subsets of circulating T cells. Incretin mimetics including semaglutide and tirzepatide showed that these drugs lower the expression of immunosuppressive proteins on CD8 T-cells in a BMI dependent fashion. [8] This suggests that GLP-1RAs may enhance T-cell-mediated immune responses by reducing the expression of inhibitory checkpoint molecules, thereby augmenting immune surveillance and tissue-protective immunity.
Clinical Case Evidence: GLP-1 Receptor Agonists in CSU
The most compelling direct evidence for GLP-1RA efficacy in mast cell-driven disease comes from two case reports involving patients with severe, antihistamine-resistant chronic spontaneous urticaria. Two female patients, aged 44 and 45 years, with long-standing chronic spontaneous urticaria inadequately controlled on high-dose H1-antihistamine therapy, were initially pre screened for participation in a clinical trial with barzolvolimab. Before trial enrollment, both initiated GLP-1RA therapy (semaglutide or tirzepatide) for metabolic indications. Remarkably, both patients achieved complete resolution of chronic spontaneous urticaria within 3 weeks of GLP-1RA initiation, with remission persisting for over 6 months. [1]
The rapidity and durability of response in these cases is particularly noteworthy. Complete resolution within three weeks represents a faster response than typically observed with omalizumab or other conventional biologics for CSU, and sustained remission extending beyond six months suggests a potentially durable therapeutic effect rather than a transient response. The fact that both patients initiated GLP-1RAs for metabolic indications rather than for CSU management represents a natural experiment, reducing the likelihood of placebo effect contributing substantially to the observed benefit.
Proposed Mechanisms Linking GLP-1 Signaling to Mast Cell Suppression
While the exact mechanisms by which GLP-1RAs exert mast cell-suppressive effects remain incompletely characterised, multiple pathways have been proposed. Several mechanisms have been proposed to explain the immunomodulatory effects of GLP-1RAs, including their influence on cytokine networks and immune cells, particularly mast cells. These observations suggest a potential immunometabolic mechanism linking GLP-1 signaling and mast cell activation, highlighting a novel therapeutic avenue for antihistamine-resistant chronic spontaneous urticaria. [1]
The immunometabolic link highlighted in the case report represents an emerging conceptual framework for understanding GLP-1RA effects beyond simple glycaemic control. GLP-1RAs may modulate mast cells through several interconnected pathways: (1) direct signaling through GLP-1R expressed on mast cell populations; (2) indirect immunomodulation through enhanced T-cell function and altered Th2/Th1 balance; (3) modulation of the metabolic microenvironment in inflammatory tissues, reducing conditions that favour mast cell activation; and (4) suppression of pro-inflammatory cytokine production from multiple immune compartments.
The broader evidence base supporting GLP-1 immunomodulation extends to several autoimmune and autoinflammatory dermatological conditions. GLP-1RAs have been reported to improve several autoimmune and autoinflammatory disorders, including dermatoses such as psoriasis, hidradenitis suppurativa, and atopic dermatitis. [1] These observations strengthen the hypothesis that GLP-1 signaling engages fundamental immunoregulatory mechanisms capable of suppressing diverse Th2-driven and innate inflammatory processes, of which mast cell activation forms a central component.
Biomarkers and Endotypes in Antihistamine-Resistant CSU
Understanding the heterogeneity of CSU through biomarker-guided endotyping may eventually enable prediction of which patients are most likely to benefit from GLP-1RA therapy. Recent research has identified several molecular markers associated with treatment response patterns and disease endotypes. A prospective study of antihistamine-resistant chronic spontaneous urticaria patients receiving omalizumab showed that the responder group had higher baseline levels of IL-2, IL-13, IL-31, and IL-33 than the non-responder group. The area under the curve of baseline IL-2, IL-13, IL-31, and IL-33 in predicting responses to omalizumab were 0.8250, 0.8125, 0.7938, and 0.7813, respectively. CSU patients with high levels of IL-2, IL-13, IL-31, and IL-33 may potentially benefit from omalizumab treatment. [9]
These cytokine profiles may provide insight into mechanistic similarities or differences between GLP-1RA response and conventional biologic response. IL-31 and IL-33 are key drivers of Th2-mediated inflammation and mast cell activation, and their elevation in some CSU patients may indicate a more mast cell-centric disease phenotype potentially amenable to GLP-1RA intervention. However, prospective studies directly examining baseline cytokine profiles in patients receiving GLP-1RAs for CSU have not yet been published.
Another relevant biomarker involves circulating eosinophils and basophils. Eosinopenia in chronic spontaneous urticaria patients is associated with type IIb autoimmunity, high disease activity, and poor response to treatment. Eosinophils should be explored as biomarkers and investigated for their contribution to the pathogenesis of chronic spontaneous urticaria. The combination of eosinopenia and basopenia is a better predictor of non-response to second-generation H1-antihistamines than eosinopenia alone (odds ratio of 9.5 vs 4.8). [10] Whether eosinophil counts predict GLP-1RA response remains unstudied but represents a hypothesis worth testing.
Mast Cell Activation Syndrome: A Broader Clinical Context
While the case reports focus specifically on CSU, the broader diagnosis of mast cell activation syndrome encompasses a more heterogeneous group of disorders characterised by multisystem symptoms arising from pathologic mast cell degranulation. An increasing number of patients are presenting to allergists with concerns about mast cell activation syndrome, often in the context of persistent, unexplained, multisystem symptoms. The prototypical presentation is idiopathic anaphylaxis, with symptoms that should be severe, episodic, typical of mast cell activation, and involve at least two organ systems. [11]
The diagnostic framework for MCAS requires objective evidence of mast cell activation. Objective evidence of mast cell activation must then be obtained, preferably by identifying an acute increase in serum tryptase on a sample drawn within four hours of an episode compared to baseline. Alternatively, urinary metabolites of mast cell mediators can be assessed by comparing baseline values with those obtained 3-6 hours post-event. Management includes instructing patients to treat acute episodes with an epinephrine auto-injector, particularly when anaphylaxis criteria are met. For patients with recurrent episodes, prophylactic therapy may be initiated, starting with H1-antihistamines and stepping-up as needed. [11]
The lack of highly specific and sensitive diagnostic biomarkers for MCAS, combined with the frequent observation of normal baseline tryptase levels in symptomatic patients, has led to underdiagnosis and therapeutic nihilism in some patient populations. This diagnostic uncertainty creates both a challenge and an opportunity for novel therapeutic approaches such as GLP-1RAs, which might address underlying immunometabolic dysfunction regardless of whether diagnostic criteria for formal MCAS are met.
GLP-1 Receptor Agonists and Metabolic Syndrome: Implications for CSU Pathophysiology
An intriguing epidemiological link exists between metabolic syndrome and treatment-refractory CSU. Comparative analysis between chronic spontaneous urticaria patient groups and control groups revealed substantial differences in terms of gender distribution, smoking habits, metabolic syndrome prevalence, waist circumference measurements, body mass index, hypertension incidence, and levels of C-reactive protein. [12] This metabolic component of CSU pathophysiology may represent a key therapeutic target for GLP-1RAs, which have well-established benefits for weight loss, glycaemic control, and cardiometabolic risk reduction.
The metabolic dysregulation implicated in CSU pathogenesis may influence mast cell function through several mechanisms, including altered immune cell trafficking, impaired regulatory T cell function, and chronic low-grade inflammation. By simultaneously addressing metabolic comorbidities and directly modulating immune cell activation, GLP-1RAs may offer a uniquely suited mechanism of action for a subset of CSU patients with associated metabolic disease.
Advantages and Limitations of GLP-1 Receptor Agonists as Emerging CSU Therapeutics
Potential Advantages
GLP-1RAs are widely used for the treatment of type 2 diabetes mellitus and obesity and are known to reduce cardiovascular risk as well as comorbidities such as kidney disease and depression. [1] This established safety and efficacy profile in large patient populations represents a substantial advantage over entirely novel biologics requiring extensive new drug development. Patients with CSU who also have metabolic comorbidities could potentially realise simultaneous therapeutic benefits across multiple organ systems.
The rapid onset of action observed in the two published cases—complete resolution within three weeks—potentially contrasts favourably with the timeline of action for approved biologics. While additional data are needed to confirm this, early response could translate to faster symptom resolution and improved quality of life for severely affected patients.
Current Limitations and Research Gaps
The most significant limitation of the current evidence base is the very small number of published cases. Two case reports, while potentially hypothesis-generating, cannot establish efficacy, optimal dosing, patient selection criteria, or durability of response across diverse patient populations. The single observation that both cases achieved sustained remission beyond six months is encouraging but insufficient to establish durable disease modification, as CSU remission can occur spontaneously in some patients and relapses can develop even after prolonged periods of stability.
No prospective, controlled trials of GLP-1RAs in CSU have been completed or published. Without such evidence, the use of GLP-1RAs for CSU remains experimental and off-label. The absence of data on potential predictive biomarkers limits the ability to identify which patients are most likely to benefit. Furthermore, optimal dosing regimens, duration of treatment, and the role of GLP-1RAs relative to established biologics remain undefined.
Distinguishing GLP-1 Mechanisms from Conventional Antihistamines and Biologics
To position GLP-1RAs appropriately within the therapeutic armamentarium for CSU, it is useful to compare their putative mechanisms with established approaches. Conventional H1-antihistamines block mast cell histamine receptors but do not address underlying mast cell activation pathways. Anti-IgE monoclonal antibodies (omalizumab) prevent IgE-Fc?R1 cross-linking, addressing one specific pathway of mast cell activation but leaving other triggers intact. Dupilumab and other newer biologics target distinct cytokine pathways (e.g., IL-4R in the case of dupilumab).
GLP-1RAs, by contrast, may operate through broader immunometabolic mechanisms affecting T-cell function, innate immune cell polarity, metabolic regulation, and potentially direct mast cell suppression. This represents a fundamentally different therapeutic approach than simple receptor blockade or single-pathway antagonism. The potential for GLP-1RAs to address multiple interconnected aspects of CSU pathophysiology simultaneously—metabolic dysregulation, Th2 skewing, mast cell dysfunction, and potentially autoimmune dysregulation—distinguishes them as a potentially transformative approach if efficacy is confirmed.
Roadmap for Future Research
Several key research priorities emerge from the current state of knowledge:
Prospective Clinical Trials:
Randomised, controlled trials comparing GLP-1RAs to placebo, conventional antihistamines, and established biologics are essential to establish efficacy, optimal dosing, and patient selection criteria. Stratification by baseline metabolic parameters, biomarkers of Th2 skewing, and disease endotype would help identify patient subgroups most likely to benefit.
Mechanistic Studies:
Detailed immunological studies in CSU patients treated with GLP-1RAs, including analysis of mast cell function (basophil histamine release assays, skin mast cell numbers and degranulation products), T-cell phenotypes, and inflammatory cytokine profiles, would illuminate the cellular and molecular basis of therapeutic response.
Biomarker Discovery:
Prospective measurement of circulating mast cell tryptase, urinary mast cell mediators, cytokine profiles, immune cell subsets, and metabolic parameters before and during GLP-1RA treatment could identify predictive biomarkers of response and enable personalised treatment selection.
Mechanistic Subgroup Analysis:
Comparative analysis of GLP-1RA response relative to response to omalizumab, dupilumab, and other biologics, linked to baseline biomarker profiles, could define “biomarker-responsive” patient subgroups and inform selection among available treatment options.
Extended Follow-up:
Long-term observational data spanning years would clarify whether GLP-1RA-induced remission persists beyond the 6-month observation period in published cases and whether dose tapering or intermittent dosing strategies might be feasible.
Mechanistic Model Systems:
Detailed in vitro studies examining GLP-1R expression and signaling on human mast cells, basophils, and related innate immune cells, combined with in vivo modelling in transgenic animal systems, would clarify direct versus indirect mechanisms of mast cell suppression.
Regulatory and Implementation Considerations
Should prospective clinical evidence support GLP-1RA efficacy in CSU, several regulatory and clinical implementation questions would require resolution. Currently, GLP-1RAs lack indication-specific regulatory approval for autoimmune or allergic conditions, rendering their use in CSU strictly off-label. Formal regulatory pathways, potentially including breakthrough therapy designation if compelling trial data emerge, might accelerate development.
Cost-effectiveness analyses would be essential, given the relatively high cost of GLP-1RAs compared to some established biologics. However, if GLP-1RAs provide metabolic and cardiovascular benefits in addition to CSU control, the overall cost-effectiveness from a societal perspective might be favourable compared to treatments addressing only CSU pathology in isolation.
Clinical algorithms for sequencing GLP-1RAs relative to established biologics would require development. The presence or absence of metabolic comorbidities, baseline disease activity, prior biologic exposure, and patient preferences regarding self-injection frequency and duration would inform treatment selection.
Conclusion
Emerging evidence from case reports suggests that GLP-1 receptor agonists, particularly semaglutide and tirzepatide, may offer therapeutic benefit in select patients with antihistamine-resistant chronic spontaneous urticaria and potentially related mast cell activation disorders. The mechanistic rationale is compelling: GLP-1 signaling modulates innate and adaptive immunity, directly impacts immune cell function including potential suppression of mast cell activation, and simultaneously addresses metabolic dysregulation implicated in CSU pathophysiology.
However, the current evidence base consists of only two published case reports with complete clinical remission, representing Level 4 (case report) evidence. This stands in stark contrast to the robust randomised controlled trial evidence supporting approved biologics for CSU. While these cases are hypothesis-generating and may herald a new therapeutic avenue, they cannot yet justify widespread adoption or constitute standard-of-care therapy.
The next essential steps involve rigorous prospective clinical trials to establish efficacy, identify predictive biomarkers and patient subgroups most likely to benefit, characterise optimal dosing regimens, and define the mechanism(s) of therapeutic action. Simultaneously, mechanistic studies should clarify whether direct GLP-1R signaling on mast cells, indirect effects through T-cell and innate immune modulation, metabolic effects, or combinations thereof account for the apparent clinical benefit. Only through such systematic investigation can GLP-1 receptor agonists transition from an intriguing case observation to an evidence-based therapeutic option for mast cell-driven diseases.
For patients with severe, treatment-refractory CSU or MCAS who have exhausted conventional options and meet criteria for GLP-1RA use based on metabolic indications, cautious consideration of GLP-1RA therapy as an experimental approach—with clear discussion of the limited evidence base and off-label nature of such use—may be justified. However, definitive therapeutic recommendations must await prospective clinical evidence. The field now stands at a critical juncture where small case observations have catalysed research interest, but substantial evidence generation remains necessary before these agents can be incorporated into evidence-based clinical algorithms for mast cell disorders.
Disclaimer: This content is for general information only and does not replace advice from your doctor, specialist, or pharmacist.
References
